TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Novartis Maintains Outlook Even As Generics Bite Into Profits

Benzinga Logo Benzinga • •By Vandana Singh
Novartis Maintains Outlook Even As Generics Bite Into Profits

Novartis reported Q3 2025 results with net sales rising 8% to $13.91 billion, driven by strong performance in key growth drugs like Kisqali and Kesimpta. The company reaffirmed its full-year guidance despite generic competition and announced a $12 billion acquisition of Avidity Biosciences.

Insights
NVS   neutral

Mixed performance with sales growth offset by generic competition, maintained full-year guidance, and strategic acquisition